Sign Up
OverviewAPI
AstraZeneca and Aerium Therapeutics advance antibody-based solutions for COVID-19 protection, particularly for immunocompromised patients. AstraZeneca's studies reveal a significant burden of COVID-19 on this vulnerable population, while Aerium Therapeutics is developing broad-spectrum antibodies to protect immunocompromised persons. The article emphasizes the need for expanded treatment options and alternative approaches to FDA approval for variant-specific antibodies.

Ask a question